Accessibility Menu
Oaktree Acquisition Corp. III Life Sciences logo

Oaktree Acquisition Corp. III Life Sciences(NASDAQ) OACCU

Market Cap$270.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)+10%
5 YearN/A
1 Year+4%
1 Month+2%
$11.00
+0.00%
+0.00Today
Oaktree Acquisition Corp. III Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 11.002026-08-28
Oaktree Acquisition Corp. III Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 11.002026-08-19
1 month+1.75%USD 10.812026-07-14
3 month+0.08%USD 10.992026-05-29
Year to date+2.7%USD 10.712025-12-31
1 year+4.06%USD 10.572025-08-28
Since inception+9.99%USD 10.002024-10-24

Oaktree Acquisition Corp. III Life Sciences Financials at a Glance

Market Cap

$270.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$6.75M

EPS (TTM)

$0.27

P/E Ratio

40.02

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$11.00

Volume

4

Open

$11.00

Previous Close

$11.00

Daily Range

$11.00 - $11.00

52-Week Range

$10.55 - $12.47

Estimated Earnings Date

Oct 1, 2025

OACCU News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences Unit operates as a special purpose acquisition company (SPAC) focused on strategic business combinations in the life sciences sector. Established in 1995 and headquartered in Los Angeles, the company aims to merge with or acquire existing enterprises to drive growth and innovation.

Products and Services
  • Special purpose acquisition company (SPAC) services
  • Strategic business combinations in life sciences
  • Investment opportunities in innovative healthcare solutions
Growth Outlook
  • Focus on high-growth life sciences sector with significant market potential
  • Strong interest from investors in healthcare innovation
  • Strategic partnerships expected to enhance market positioning
Financial Highlights
  • Recent quarterly net income of $1,394,121, reflecting operational efficiency
  • Trailing twelve months (TTM) price-to-earnings ratio of 37.16, indicating growth potential
  • Cash and short-term investments totaling $1,276,930, providing liquidity for future investments
Oaktree Acquisition Corp. III Life Sciences Unit is positioned to capitalize on the growing demand for innovative healthcare solutions. The company's focus on strategic acquisitions within the life sciences sector aligns with current market trends, making it an attractive option for investors interested in the healthcare industry. Recent financial performance demonstrates operational efficiency and a solid cash position, which may support future growth initiatives. The emphasis on partnerships and market positioning further enhances the potential for long-term success.
AI Generated • Aug 11, 2026

Industry

Banks

Sector

Financials

Employees

3

CEO

Zaid Pardesi, MBA

Website

www.oaktreeacquisitioncorp.com/oac-iii

Headquarters

Los Angeles, CA 90071, US

OACCU Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

3.46%

Return on Capital

-0.61%

Return on Assets

3.27%

Earnings Yield

2.50%

Dividend Yield

0.00%

Payout Ratio

62.89%

Stock Overview

Market Cap

$270.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

24.58M

Volume

4

Avg. Volume

43.344

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.20M

EBITDA

-$1.20M

Operating Cash Flow

-$455.69K

Capital Expenditure

$3.00

Free Cash Flow

-$455.69K

Cash & ST Invst.

$1.18M

Total Debt

$11.82K

Oaktree Acquisition Corp. III Life Sciences Performance Analysis

Oaktree Acquisition Corp. III Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Oaktree Acquisition Corp. III Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Oaktree Acquisition Corp. III Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD 0.05N/A
20252025-12-31USD 0.30447.0%
Oaktree Acquisition Corp. III Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-305.0%
Q42025-12-31-9.0%
Q12026-03-31-17.6%
Q22026-06-3016.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$270.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$90.13M

N/A

Employees

3

N/A

Net Income

$1.60M

-14.4%

EBITDA

-$261.96K

+2.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.18M

-14.8%

Total Debt

$11.82K

+0.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$11.82K

+0.0%

Return on Assets

3.27%

N/A

Return on Invested Capital

-0.59%

N/A

Free Cash Flow

-$97.26K

+26.3%

Operating Cash Flow

-$97.26K

+26.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TLNCUTalon Capital Corp.
$10.44+0.19%
BDCIUBTC Development Corp. Unit
$10.25+0.00%
SVACSpring Valley Acquisition Corp. III Class A Ordinary Shares
$9.12+0.00%
NHICNewHold Investment Corp III
$10.59-0.09%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About OACCU

What is the current price of Oaktree Acquisition Corp. III Life Sciences?

Oaktree Acquisition Corp. III Life Sciences is trading at $11.00 per share.

What is the 52-week range for Oaktree Acquisition Corp. III Life Sciences?

Over the past 52 weeks, Oaktree Acquisition Corp. III Life Sciences has traded between $10.55 and $12.47.

How much debt does Oaktree Acquisition Corp. III Life Sciences have?

As of the most recent reporting period, Oaktree Acquisition Corp. III Life Sciences reported total debt of $11.82K.

How much cash does Oaktree Acquisition Corp. III Life Sciences have on hand?

Oaktree Acquisition Corp. III Life Sciences reported $1.18M in cash and cash equivalents in its most recent financial results.

What is Oaktree Acquisition Corp. III Life Sciences’s dividend yield?

Oaktree Acquisition Corp. III Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services